26 September 2021>: Articles
Pulmonary Tuberculosis After Therapy with Anti-Tumor Necrosis Factor (TNF) for Crohn Disease: A Case Report
Challenging differential diagnosis, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
Douglas Inomata Cardoso da Silva A , Bruna Helena de Oliveira Santos B , Fernanda Lofiego Renosto B , Erika Mayumi Watanabe B , Giédre Soares Prates Herrerias A , Rogerio Saad-Hossne A , Julio Pinheiro Baima A , Ligia Yukie Sassaki A*DOI: 10.12659/AJCR.932963
Am J Case Rep 2021; 22:e932963
Table 1. Biochemical tests and clinical treatment.
Reference values | 04/02/2019 | 29/03/2019 | 15/04/2019 | 18/06/2019 | 18/08/2019 | 27/04/2020 | 18/09/2020 | 12/2020 | |
---|---|---|---|---|---|---|---|---|---|
Hematocrit (%)/hemoglobin (g/dL) | 41–53/13.5–17.5 | 38.9/12.9 | 45/15.1 | – | 45/15 | 36.1/12.4 | 47.6/16.3 | 49.3/16.7 | 50.7/16.9 |
Platelets (10/mm) | 140–440 | 164 | 155 | – | 174 | 298 | 150 | 151 | 151 |
Leukocytes (10/mm) | 4–11 | 5.1 | 5.1 | – | 6.9 | 5.3 | 5 | 4.6 | 4.9 |
Aspartate amino transferase (U/L) | 17–59 | 35 | 65 | 116 | 31 | 20 | 127 | 29 | 32 |
Alanine amino transferase (U/L) | 36 | 66 | 212 | 26 | 15 | 114 | 22 | 22 | |
Gama glutamyl transferase (U/L) | 15–73 | 71 | 94 | 544 | 35 | 124 | – | 52 | 37 |
Alkaline phosphatase (U/L) | 36–126 | – | 51 | 119 | 46 | 73 | – | 54 | 50 |
Total bilirubin/direct bilirubin (mg/dL) | 0.2–1.3/0–0.3 | 0.4/0 | – | – | 0.6/0 | 0.5/0 | – | 0.5/0 | 0.9/0 |
Albumin (g/dL) | 3.5–5 | 3.4 | 4.2 | - | - | 2.5 | – | 4.4 | 4.9 |
Amylase (U/L) | 30–110 | 203 | – | 114 | 116 | -– | – | 102 | – |
C-reactive protein (mg/dL) | 6 | 0.5 | – | 1.1 | 4.7 | 0.5 | 0.5 | 0.5 | |
Erythrocyte sedimentation rate (mm/h) | – | 4 | – | 27 | 104 | – | 2 | 2 | |
Medical treatment | Prednisone + azathioprine | Prednisone + azathioprine | Adalimumab | RIPE (14/08/19-14/10/19) | RI (15/10/19-18/05/20) | Mesalazine | |||
RIPE – rifampicin, isoniazid, pyrazinamide, and ethambutol; RI – rifampicin and isoniazid. |